Allogene Therapeutics' Dr. David Chang, M.D., Ph.D. To Transition From President and Chief Executive Officer, Effective On June 30, 2026; Co. Elects Zachary Roberts, M.D., Ph.D. As President And Chief Executive Officer, Effective July 1, 2026